Oncologists want more treatment options for advanced lung cancer patients, new survey says
Oncologists are encouraged by the number of immunotherapies to treat non-small cell lung cancer, but they still want more options, especially for advanced cases, according to a new Harris Poll survey commissioned by Regeneron and the Cancer Research Institute.
The overwhelming majority of advanced NSCLC patients have used immunotherapy as a first-line (97%) or second-line (86%) treatment, according to the 250 oncologists surveyed, but 30% of those physicians say there’s still room for more options. Fewer than one in five oncologists rated the current options as “excellent.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.